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Abstract 
 
Embryonal tumours of the CNS present a significant clinical challenge. Many of these 
neoplasms affect young children, have a very high mortality and therapeutic strategies are 
often aggressive with poor long-term outcomes. There is a great need to accurately diagnose 
embryonal tumours, predict their outcome and adapt therapy to the individual patient’s risk. 
For the first time in 2016, the WHO classification took into account molecular characteristics 
for the diagnosis of CNS tumours. This integration of histological features with genetic 
information has significantly changed the diagnostic work-up and reporting of tumours of the 
CNS. However, this remains challenging in embryonal tumours due to their previously 
unaccounted tumour heterogeneity. We describe the recent revisions made to the 4th edition 
of the WHO classification of CNS tumours and review the main changes, whilst highlighting 
some of the more common diagnostic testing strategies.  
 
Introduction 
Since the last version of the WHO classification of tumours of the CNS in 2007 (1), molecular 
investigation has revolutionised our understanding of embryonal tumours of the CNS. This has 
largely been driven by genome-wide studies characterising prevalent genetic events and 
biological features. These have led to tumour reclassification, sub-typing and identification of 
novel entities (2,3). However, many unanswered questions remain about the clinical impact of 
this knowledge, the best way to implement testing in clinical practice and how to manage the 
tumours that, despite molecular advances, defy standard classification. 
 
Implementation of the integrated diagnosis for embryonal tumours 
While the WHO classification 2007 relied on histological features only, the challenge of its 
update in 2016 was to integrate meaningful genetic information to enable a more precise 
classification, while maintaining continuity with the previous editions (4). This integrated 
diagnosis would be presented in a layered format; including the histological diagnosis, WHO 
grade, molecular genetic information and ultimately the integrated diagnosis. The value of this 
approach is clearly illustrated in embryonal tumours, in particular medulloblastoma, where the 
combination of molecular and histological data provides discrete diagnostic information 
(Figure 1) (2,4).  
 
For non-medulloblastoma and non-AT/RT embryonal tumours, diagnostic classification has 
been a major challenge. These tumours were formerly called supratentorial or CNS-primitive 
neuro-ectodermal tumours (PNET) (1). Up until now, “CNS-PNET” has been used as an 
umbrella term for a range of biologically different tumours. Several molecular profiling studies 
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on tumours previously diagnosed as CNS-PNET showed that a wide range of biologically 
different tumours existed within this entity, some of which were incorrectly assigned (5-7). 
These encompassed other well-recognised tumour types (e.g. high-grade gliomas and 
sarcomas), recently redefined entities (e.g. embryonal tumour with multi-layered rosettes, 
ETMR) as well as novel tumour types (2). 
 
The clinical importance of molecular classification 
The correct diagnosis of paediatric tumours is critical for their treatment because of the 
balance required between achieving a long-term cure and avoiding treatment related disability 
in survivors. It is essential to recognise those children with a poor prognosis who can either 
receive escalated treatment or be offered palliative care, versus those with a good prognosis 
for whom treatment might be reduced to prevent long term complications. This is perhaps 
again best illustrated in medulloblastoma, where overall survival rates are 65-70% after 
5 years (8). However, there are significant cognitive, endocrine and neurological complications 
in the majority of survivors (9,10). These individuals are significantly less likely to complete 
education and live independently when compared to age matched controls.  
 
Medulloblastoma 
Four medulloblastoma genetic entities are now recognised by WHO 2016 classification (4). 
These are: 1) WNT-activated (MBWNT); 2) SHH-activated (MBSHH), TP53 wildtype; 3) SHH-
activated (MBSHH), TP53 mutant; 4) Non-WNT/Non-SHH medulloblastoma. The latter can be 
further subdivided with DNA methylation or mRNA expression profiling into “group 3” and 
“group 4” (11). These variants are considered provisional because it is not absolutely clear to 
what extent they represent distinct diseases, multiple subtypes or variants of a single entity. 
Table 1 describes their most commonly associated genetic changes and the diagnostic 
histological variants. It is essential that according to the revised WHO classification 2016, 
every diagnosis of medulloblastoma should result in an integrated diagnosis with a histological 
part and a genetically defined part as both aspects provide clinically important 
information (12). 
 
Genetically defined medulloblastoma 
Around 10% of medulloblastomas fall into the MBWNT subgroup and most display classic 
histology (3). Over 90% of MBWNT are associated with point mutations in exon 3 of the 
CTNNB1 (beta-catenin) gene. Mutations in CTNNB1 or (at lower frequencies) other 
components of the WNT signalling pathway (e.g. AXIN1, AXIN2 and APC) lead to the 
pathway’s constitutive activation with accumulation of the ß-catenin protein in the nucleus, 
identifiable by immunohistochemistry (IHC). Monosomy for chromosome 6 is present in about 
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85% of cases, and may aid in supporting a diagnosis of MBWNT. Importantly, MBWNT has an 
excellent overall prognosis in children (>90% survival) following surgery and current treatment 
protocols (3). Clinical trials are underway in Europe and North America to determine if 
treatment intensity can be safely reduced for these tumours, thus also reducing treatment-
related long term developmental and cognitive disabilities without affecting survival rates (13). 
However, it should be noted that the adults with MBWNT do not show the same prognostic 
advantage (14). 
 
Approximately 30% of medulloblastomas show activation of the sonic hedgehog signalling 
pathway signalling (3). The status of TP53 further divides MBSHH into two entities with 
completely different clinical outcomes (15). MBSHH tumours with TP53 mutations have a dismal 
prognosis and are considered very high-risk. A significant number of these patients (~50% in 
one series) carry germline mutations in TP53 and their treatment is especially challenging due 
to their susceptibility to secondary tumours following radiotherapy (16). MBSHH patients without 
TP53 mutations are considered lower-risk but many of these, particularly young children, carry 
germline mutations in PTCH1 or SUFU which can alter treatment strategies (17). Therefore, 
genetic counselling should be considered for all families with children with medulloblastomas 
with SHH activation. 
 
Non-WNT/non-SHH medulloblastomas are provisionally divided into group 3 (MBgrp3) and 
group 4 (MBgrp4), which account for approximately 20% and 40% of all medulloblastomas 
respectively. However, the diagnostic status of the non-WNT/non-SHH subtypes is likely to 
develop over the next few years. 
 
Histologically defined medulloblastoma 
The histological subtypes of medulloblastoma have not changed in a major way in the update 
of the 4th edition of the WHO classification (see Table 1) (1,4). Large cell and anaplastic 
variants have been combined into a single entity, reflecting their frequent coexistence together 
with the clinically uniform approach to this group. This tumour type has a very poor prognosis. 
Furthermore, the melanotic and myoblastic forms have been regarded as tissue patterns 
rather than specific entities, reflecting their extreme rarity. Finally, an emphasis is made in 
defining the desmoplastic/nodular medulloblastoma subtype by reticulin staining. The key 
feature in defining this subtype is that the nodules are surrounded by reticulin-rich tissue. This 
allows distinction between classic medulloblastoma with a biphasic architecture, which has 
nodules but no desmoplasia (regarded as a variant of classic medulloblastoma) from 
desmoplastic/nodular medulloblastoma which has not only nodular architecture but extensive 
reticulin rich desmoplasia between the nodules.  
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Overlap exists between molecular and histological subtypes; for example, MBWNT almost 
always has classic histology, while desmoplastic/nodular MB and MB with extensive nodularity 
are MBSHH. However, MBSHH can have classic or anaplastic histology and occasional 
anaplastic MBWNT cases have been reported. The interplay between molecular and histological 
subtype is imperfectly understood and their relationship to outcome is yet to be addressed in 
a systematic way. 
 
Prognostic markers of medulloblastoma 
In addition to the molecular techniques needed to classify medulloblastoma, there are 
molecular markers that provide additional prognostic information. The two markers for which 
there is the best data and are offered routinely are amplification of MYC or MYCN; presence 
of either of these has been associated with a worse outcome (18). However, recent data 
suggests that the prognostic significance of these markers depends on the genetically defined 
medulloblastoma entity. MYC amplification is usually seen in non-WNT/non-SHH 
medulloblastomas and these patients have a poor prognosis. While amplification of MYCN in 
MBSHH indicates a very poor outcome, its prognostic value in non-WNT/non-SHH 
medulloblastomas is less clear (8). 
 
Recent classification of medulloblastoma 
Larger datasets have recently suggested more medulloblastoma subgroups than the current 
WHO recognises. One study proposes seven genetic entities based on clustering algorithms, 
with each existing group except MBWNT being further divided into high and low-risk (8); while 
another suggests a total of 12 subgroups based on the integration of transcriptomic and 
methylation data (19). Further exploration of the clinical significance of these subtypes will 
reveal how the next WHO classification may need to be adapted.  
 
Relapsed medulloblastoma 
Relapsed medulloblastoma has a uniformly bad outcome (20). There is a great need to 
understand the tumours at the point of relapse, especially their mechanisms of resistance. At 
relapse, medulloblastoma has been shown to maintain the same genetically-defined subtype 
but may change morphological subtype, for example towards a more anaplastic 
pathology (21). Furthermore, acquisition of additional genetic events at relapse can also have 
a clinical impact. Combined abnormalities of MYC and TP53 occur in a subpopulation of 
relapsed medulloblastoma and are associated with a very poor prognosis (22). In mouse 
models, these tumours can be targeted therapeutically and suggests that it will be important 
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to undertake diagnostic testing on the relapsed tumour both to predict outcome but also to 
predict response to treatment.  
 
Spatial heterogeneity studies in medulloblastoma suggest that actionable drug targets (i.e. 
mutations) are unevenly distributed across the tumour mass (23). This indicates that subclonal 
events underlying tumour heterogeneity may be responsible for drug resistance, which also 
puts into question the efficacy of targeted monotherapies, especially in the presence of 
subclonal events at relapse (24). 
 
Non-medulloblastoma embryonal tumours 
 
Embryonal tumour with multilayered rosettes (ETMR) 
The recognition of embryonal tumour with multilayered rosettes, C19MC-altered as a distinct 
tumour type is a major change in recent years. Historically, these tumours have been 
described under a range of morphological entities: embryonal tumour with abundant neuropil 
and true rosettes (ETANTR), ependymoblastoma and medulloepithelioma (Figure 1) (25). 
These tumours harbour an amplification on chromosome 19 of a large miRNA cluster 
(C19MC) (26,27), which can be readily identified by FISH. This region is associated with a 
suspected area of genetic instability, leading to the fusion of TTYH1 with C19MC (28). 
Although not specific to ETMRs, LIN28A is typically expressed in ETMRs (LIN28A is also 
expressed in some germinomas and occasionally in AT/RT) and detection by IHC is a useful 
screening test to alert to the possibility of an ETMR and the need for C19MC amplification 
testing (29). The clinical behaviour of ETMR is typically that of rapid progression and in most 
cases, they are unresponsive to conventional therapy. Therefore, immunohistochemically, 
molecularly and clinically, ETMRs form a relatively uniform group of infant CNS tumours with 
generally abysmal outcomes. Many of the tumours previously called medulloepithelioma will 
fall into this group but there are medulloepitheliomas that while expressing LIN28A, lack 
C19MC amplification (6) which according to the current WHO classification should be 
regarded as a separate entity (4). Finally, ETMR, NOS should be assigned when multilayered 
ependymoblastic rosettes are identified, but there is no C19MC alteration detected or when 
testing for the alteration has not been undertaken.  
 
Atypical teratoid/rhabdoid tumours (AT/RT) 
AT/RT has been a well-established tumour entity for many years and has been recognised in 
previous editions of the WHO (1). However, the demonstration of SMARCB1 (INI1) loss or 
very rarely loss of SMARCA4 (BRG1), also a component of the SWI/SNF chromatin 
remodelling complex, has become a diagnostic requirement (Table 2). This reflects the long-
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accepted definition of these as high-grade CNS tumours characterised by inactivation of these 
genes (30). In instances where tumour morphology is consistent with AT/RT but displays 
positive nuclear staining for SMARCB1, SMARCA4 loss should be confirmed. 
 
Several studies have indicated the presence of molecular AT/RT subtypes associated with 
differences in clinical and treatment responses and consensus is underway in order to better 
inform molecular stratification of these tumours and determine if this will become clinically 
relevant (31,32). A separate category for CNS embryonal tumour with rhabdoid features has 
been retained for tumours in which either the genes are intact or their status cannot be 
determined (4). 
 
Other CNS embryonal tumours 
The generic term ‘embryonal tumours’ has replaced CNS primitive neuroectodermal tumours 
(CNS-PNET) in the WHO 2016 classification (Figure 1). This separates the current 
terminology from historical concepts of PNET covering a diverse range of CNS tumours 
(medulloblastoma and supratentorial PNET) and from potential confusion from tumours of the 
same name arising outside the nervous system (e.g. Ewing’s type sarcoma/peripheral 
PNET) (33,34). CNS embryonal tumours include the following morphological subtypes: 
medulloepithelioma, CNS neuroblastoma, CNS ganglioneuroblastoma and CNS embryonal 
tumour, NOS. The diagnosis of embryonal tumour therefore requires active exclusion of other 
embryonic specific entities (e.g. ETMR and AT/RT). Furthermore, a proportion of tumours 
previously described as CNS-PNET can be re-diagnosed as a number of other tumour types 
(e.g. glioblastoma, ependymoma, Ewing’s sarcoma) (35,36) and these must also be excluded. 
Table 2 includes an overview of useful diagnostic IHC testing that can be performed with 
respect to making a diagnosis of embryonal tumour. 
 
Recent data has defined four tumour entities based on methylation profiling; some of which 
historically would have been diagnosed as CNS-PNET, along with other tumour types (36). 
Sequencing for recurrent mutations identified common gene fusions in a proportion of cases 
belonging to these subgroups. CNS neuroblastoma with FOXR2 activation (NB-FOXR2) was 
characterised by FOXR2 fusions, which may come to encompass CNS neuroblastomas and 
CNS ganglioneuroblastomas. High-grade neuroepithelial tumours with MN1 alteration 
(HGNET-MN1) typically contain MN1 fusions (identifiable by FISH), although a robust 
immunohistochemical marker is missing. Morphological similarities have been noted to the 
glial neoplasm, astroblastoma. The Ewing’s sarcoma family tumour with CIC alteration (EFT-
CIC) have CIC structural variants, which can be detected by break-apart FISH and are typically 
characterised by positive NUTM1 nuclear staining. Finally, the BCOR-altered neuroepithelial 
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tumours are defined by a BCOR duplication (and rarely point mutations) in exon 15. Both these 
entities may reflect mesenchymal/sarcomatous tumours which occur in other parts of the body 
and not limited to the CNS.  
 
Due to the rarity of these novel tumour entities, risk stratification, assessment of clinical 
significance and selection of appropriate therapeutic strategies will be immensely challenging. 
However, preliminary clinical data from a total of 31 patients did suggest differences in survival 
rates; with the HGNET-MN1 group associated with the best prognosis (36). 
 
Pineoblastoma 
Pineoblastomas histologically resemble CNS embryonal tumours but arise from the pineal 
gland. They are treated according to the same protocols as embryonal tumours and show poor 
prognosis, although studies suggest that adults and children do better than infant 
cases (37,38). Histologically, they are composed of sheets of densely packed hyperchromatic 
cells with strong staining for neuronal markers (e.g. synaptophysin). Cytogenetic studies 
describe pineoblastomas as having fewer alterations compared with other embryonal 
tumours (39) and similarly, recurrent genetic changes beyond germline RB1 mutations (linked 
to retinoblastoma) and DICER1 are yet to be identified (40). Retinoblastoma and 
pineoblastoma can coincide in patients with trilateral retinoblastoma due to common 
developmental lineages and the retinal transcription factor, CRX has been identified as a 
possible marker of some pineal tumours, although its interpretation may be somewhat 
challenging depending on the age and quality of the tissue (41,42). 
 
Pineal anlage tumours are very rare pineal tumours with heterologous differentiation alongside 
a primitive neuroectodermal component. They typically contain melanin and the heterologous 
elements may exhibit skeletal muscle or chondroid differentiation (43). There are no molecular 
studies that indicate whether there are distinctive diagnostic molecular features of this tumour. 
 
Pituitary blastoma 
An extremely rare entity that is considered an embryonal tumour of the pituitary gland is the 
pituitary blastoma (44). There are 13 infant cases described in the literature and a germ-line 
mutation in DICER1 is reported to be a key predisposing event (45).  
 
Concluding remarks 
In terms of diagnostic approaches, transparency is needed on how molecular and 
immunohistochemical tests are ideally performed and interpreted for optimal guidance of 
therapeutic management. For medulloblastoma, recent guidelines for clinical diagnosis have 
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been published (46) and similar information should be made available for the other entities. 
DNA methylation and transcriptomic based clustering approaches are proving greatly valuable 
but are not widely accessible, nor are such methods fully validated for clinical diagnosis. 
Obviously, insufficient material for genetic screening may lead to uncertainty and not all 
centres may currently have access to the necessary facilities to implement a fully integrated 
diagnosis. 
 
Since the publication of the WHO 2016 classification, additional heterogeneity within the 
medulloblastoma subtypes and other embryonal tumour groups has already been 
identified (8,19,36) and we anticipate additional molecular findings are likely to influence the 
next WHO revision. As existing tumour groups are further sub-divided into distinct groups, the 
rarity of these tumours will challenge risk-stratification and assignment of appropriate 
therapeutic strategies, while archival studies will be key in identifying defining molecular 
signatures of currently unclassifiable tumours.  
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Legends 
 
Figure 1. Summary of the major changes in the WHO 2016 classification for the 
diagnosis of CNS embryonal tumours 
In the 2007 WHO classification tumours were histologically defined. In the current edition, an 
integrated diagnosis combines histology with genetically defined tumours. For embryonal 
tumours, this has meant four new genetic subgroups of medulloblastoma. The CNS-PNET 
entity is no longer recognised, instead ETMRs form their own embryonal entries, while any 
remaining tumours are currently classified based on histology alone and fall under “other 
embryonal tumours”. This group of genetically undefined tumours contains 
medulloepithelioma, CNS neuroblastoma, CNS ganglioneuroblastoma and CNS embryonal 
tumour, NOS. *: provisional subentity, NOS: not otherwise specified.  
 
 
Table 1. WHO 2016 classification of medulloblastoma subtypes, characterised by 
genetic and histological features 
The most common features associated with each molecular (A) and histological (B) subgroup 
for medulloblastoma are described. The tables aid as a good basis for completing an 
integrated diagnosis of medulloblastoma. For a more comprehensive list, the reader is advised 
to refer to the WHO 2016 classification, pages 184-185.  
 
 
Table 2. WHO 2016 classification of non-medulloblastoma embryonal tumours 
The key diagnostic features associated with non-medulloblastoma embryonal tumours are 
described. For a diagnosis of embryonal tumours, NOS it is necessary to actively exclude 
alternative possibilities (e.g. ETMR, high-grade glioma, ependymoma etc.) and if possible, it 
may be worth considering a DNA methylation array to see if the tumour matches previously 
identified molecular profiles. For more details, the reader is advised to refer to the WHO 2016 
classification, pages 201-212.  
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A. Medulloblastoma, genetically defined 
WHO 
entity 
Histological 
features 
Special 
stains/immunohistochemist
ry 
Key molecular features 
WNT 
activated Usually classic 
Nuclear b-catenin positive (>5-
10% of cells) 
Nuclear YAP1 positive, 
nuclear OTX2 positive 
GAB1 negative, p75NGFR 
negative 
Mutation in exon 3 of CTNNB1 
(b-catenin) 
Monosomy of chromosome 6 
Typical WNT profile on 
methylation and transcriptome 
analysis  
SHH 
activated, 
TP53 
wildtype 
Any variant. 
Includes all 
nodular/desmopla
stic 
medulloblastomas 
and MBEN 
No significant nuclear b-
catenin, 
Nuclear YAP1 positive, 
nuclear OTX2 negative, 
GAB1 positive, p75NGFR 
positive 
No mutation of TP53 
Typical SHH-profile on 
methylation and transcriptome 
analysis 
SHH 
activated, 
TP53 
mutant 
Any variant, often 
anaplastic 
No significant nuclear b-
catenin, 
Nuclear YAP1 positive, 
nuclear OTX2 negative, 
GAB1 positive, p75NGFR 
positive, 
Mostly nuclear p53 positive  
Mutation of TP53 
Typical SHH-profile on 
methylation and transcriptome 
analysis 
Frequently MYCN or GLI2 
amplification 
Non-
WNT/non-
SHH 
(Group 3 or 
Group 4) 
Any variant 
except 
desmoplastic/nod
ular or MBEN 
No significant nuclear b-
catenin 
Nuclear YAP1 negative, 
nuclear OTX2 positive 
GAB1 negative, p75NGFR 
negative 
MYC or MYCN amplification in 
some but not diagnostic 
Typical Group 3 or Group 4 
profile on methylation and 
transcriptome analysis 
 
B. Medulloblastoma, histologically defined 
WHO 
entity 
Histological 
features 
Special stains/ 
immunohistochemistry Key molecular features 
Classic 
Lacks 
intratumoural 
desmoplasia or 
significant (diffuse 
and severe) 
anaplasia 
Reticulin staining shows a lack 
of nodular desmoplasia 
Frequent phenotype across all 
4 molecular categories 
 
Desmoplas
tic/ Nodular 
Nodular with 
internodular 
desmoplasia, can 
be present in 
minor areas only 
Reticulin staining highlights 
internodular desmoplasia. 
SHH phenotype (nuclear 
YAP1 positive, GAB1 positive, 
p75NGFR positive, nuclear 
OTX2 negative, no significant 
nuclear b-catenin) 
SHH-activated molecular 
profiles 
Medullobla
stoma with 
extensive 
nodularity 
Abundant and 
large irregular 
nodules with 
internodular 
desmoplasia 
Reticulin staining highlights 
internodular desmoplasia. 
Advanced neurocytic 
differentiation in islands with 
strong nuclear NeuN 
expression. 
SHH phenotype (nuclear 
YAP1 positive, GAB1 positive, 
p75NGFR positive, nuclear 
OTX2 negative, no significant 
nuclear b-catenin) 
SHH-activated molecular 
profiles 
17 
Large 
cell/anapla
stic 
Predominant 
large cell and/or 
anaplastic 
phenotype of 
tumour cells  
Large cell cytology is 
frequently associated with dot-
like synaptophysin expression. 
P53 accumulation may hint to 
SHH-activated cases with 
TP53 mutation. 
Mostly non-WNT/non-SHH 
molecular profiles, also in SHH 
medulloblastoma, TP53 
mutated. 
Frequent MYC gene 
amplification in tumour with 
large cell phenotype. 
Anaplasia may hint to TP53 
mutated SHH activated 
medulloblastomas. 
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WHO entity Diagnostic investigations 
ETMR, C19MC altered LIN28A positive [IHC] C19MC amplification [FISH or array] or fusion (RT-PCR) 
ETMR, NOS Multilayered ependymoblastic rosettes but C19MC alteration either not detected or testing for this alteration not undertaken 
Medulloepithelioma LIN28A positive No detectable C19MC amplification 
AT/RT SMARCB1 or SMARCA4 loss [IHC sufficient, can be confirmed by sequencing but not required] 
CNS embryonal 
tumour with rhabdoid 
features 
SMARCB1 and SMARCA4 retained but showing rhabdoid features 
CNS neuroblastoma 
Immunohistochemical evidence for neuroblastic/neuronal 
differentiation (synaptophysin-positive) 
LIN28A negative, SMARCB1 and SMARCA4 retained 
CNS 
ganglioneuroblastoma 
Immunohistochemically similar to CNS neuroblastoma but with 
groups of prominent ganglion cells 
LIN28A negative, SMARCB1 and SMARCA4 retained 
CNS embryonal 
tumour, NOS 
Requires active exclusion of other diagnoses: 
- AT/RT: SMARCB1 and SMARCA4 intact 
- ETMR: no LIN28A expression or C19MC amplification 
- Soft tissue tumours/Ewing’s sarcoma: no membranous CD99 
[IHC], EWSR1 or CIC/NUT rearrangement not present [FISH, RNA-
seq] 
- Ependymoma: no C11orf95-RELA fusion [FISH], L1CAM and/or 
nuclear p65/RelA expression [IHC]  
- High grade astrocytoma: no mutations in H3.1, H3.3, ATRX, 
IDH1/2 [IHC, sequencing needed to exclude the presence of H3F3A 
G34 mutation] 
- Consider methylation profiling 
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